Scale diagnostic Cepheid’s large installed base of GeneXpert systems and broad test portfolio across infectious diseases present ongoing opportunities to upsell expanded test menus, higher throughput cartridges, and maintenance contracts to expand automation in central laboratories and near-patient settings.

Healthcare expansion As a part of Danaher, Cepheid benefits from a broader diagnostics ecosystem, enabling cross-sell of complementary assays, data management, and workflow optimization solutions to existing Danaher customers and partners seeking integrated molecular testing.

Global reach Cepheid targets institutions of various sizes worldwide; this creates potential for tiered offerings such as scalable deployment, training programs, and remote monitoring to capture mid-market and large hospital networks seeking standardized PCR capabilities.

Financial readiness With substantial revenue and a defined funding backdrop, there is room to propose financing options, multi-year service agreements, and performance-based ROI cases to buyers evaluating total cost of ownership for rapid molecular testing.

Innovation leverage Cepheid’s focus on fast, accurate molecular diagnostics aligns with rising demand for rapid pathogen detection and emerging infectious disease testing, suggesting opportunities to partner on new assay development, clinical studies, and expanded oncology/genetics panels.